Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Alcool isopropylique inhalé pour le traitement des nausées

21 septembre 2026 mis à jour par: Susana Ruano, State University of New York at Buffalo

Alcool isopropylique inhalé pour le traitement des nausées dans un service d'urgence pédiatrique : essai clinique contrôlé randomisé ouvert

To determine the efficacy of inhaled isopropyl alcohol in treating nausea/vomiting among pediatric patients compared with the conventional ondansetron, or placebo treatment in a tertiary care pediatric emergency department.

Aperçu de l'étude

Description détaillée

I. Obtaining consent Our study personnel will approach the treating physician in the ED once a patient is suspected to be eligible for the study. The physician will determine patient's eligibility by using the screening sheet. If a patient meets all study inclusion and exclusion criteria, our study personnel will approach the legal guardian/patient in the private patient room and introduce the study to them. Enough time will be given to the patient and their legal guardian to allow them review and understand the consent/assent. All questions will be answered before obtaining the consent. Once the consent/assent is obtained from the legal guardian and participant, our study personnel will keep the treating physician and bedside nurse posted about the enrollment.

II. Randomization of subject

There will be three arms of this study:

  1. Conventional oral ondansetron (Zofran) treatment group,
  2. Inhaled isopropyl alcohol treatment group,
  3. Inhaled normal saline (placebo) group. After obtaining informed consent, the patients will be randomized into one of the three groups following a randomization table created by a statistician.

Whichever intervention is randomly selected will be used to treat the subject. Our research team member will notify the treating physician and the bedside RN about the assignment.

If the subject is assigned to receive ondansetron treatment, subject will be provided with 4 mg ondansetron oral disintegrating tablet (ODT) for treatment.

If the subject is assigned to receive the isopropyl alcohol pad group, an isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) will be given to the subject, or the legal guardian . The alcohol pad will be held 1-2 cm under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed during the ED stay.

If the subject is assigned to receive the inhaled placebo, a normal saline pad (Hygea sterile saline wipe) will be given to the subject or the legal guardian. The saline wipe will be held under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed.

For those subject who receives normal saline or alcohol pad treatment, if their vomit/nausea symptoms has not improvement after 30 minutes post intervention, they may receive Zofran treatment in the ED.

III. Data collection A paper data collection form will be used to collect data in the ED, which is attached with this submission. Patient ID sticker with name, MRN, FIN, and DOB will be placed on the data form. This data form will be completed by the ED research assistant. The completed data form as well as the signed informed consent document will be placed in a locked study data box in the ED. The study coordinator will collect these documents from the ED periodically, and transfer the documents to the UBMD Pediatrics Department Research Office (5th Floor Conventus, 1001 Main St, Buffalo, NY 14203). All paper documents will be stored in locked file cabinet in the office.

Two databases will be created for this study, the Subject Database and the PHI database. Subject identifiable information will be entered in the PHI database, which include: MRN, FIN, and DOB. All other data elements will be entered in the Subject Database. Certain PHI e.g. ED visit/discharge date, study intervention administration date will also be entered in the Subject database for the convenience of data analysis. A unique study ID will be assigned to each subject, this ID number will be used as the code key to link the paper data form, Subject Database and PHI database. Both databases will be saved in study coordinator's password protected UPA online drive, the PHI database will be double secured by a code.

Data Collection:

  1. Demographic data: Patient age, sex, race, and ethnicity

  2. Baxter Animated Retching Faces nausea score at: Baseline (prior to intervention), 10 minutes post-intervention, 30 minutes post-intervention, and at ED discharge.

    The 10 minute post-intervention timepoint was selected because prior research in adult post-operative patients has shown that inhaled isopropyl alcohol significantly improved nausea on surveys conducted 5, 10, and 15 minute after inhalation.6 The 30 minute post-intervention timepoint was selected because the onset of action for ondansetron oral disintegrated tablet is within 30 minutes.132 We will reassess nausea symptoms at ED discharge to account for any anti-emetic benefit that may have only be transient.

  3. ED clinical information about vomiting and apparent aspiration

  4. Patient/caregiver perceived side effects of treatment

  5. Satisfaction scores: From both the bedside nurse and the patient's caregiver

  6. Cross-over information: Did the patient use a treatment other than the assigned treatment (e.g. if the patient was in the inhaled isopropyl alcohol group, did they cross-over into the ondansetron ODT group)

  7. ED discharge information: Length of stay, patient disposition and discharge diagnosis

Type d'étude

Interventionnel

Inscription (Estimé)

84

Phase

  • Phase 2
  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Haiping Qiao, MBBS, MS
  • Numéro de téléphone: 7163230055
  • E-mail: hqiao@upa.chob.edu

Sauvegarde des contacts de l'étude

Lieux d'étude

    • New York
      • Buffalo, New York, États-Unis, 14203
        • Recrutement
        • Oishei Children's Hospital
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

7 ans à 17 ans (Enfant)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patients with a chief complaint of nausea or vomiting
  • Ages 7-178 years, both sexes
  • Weight ≥ 15 kg
  • Baxter Animated Retching Faces (BARF) nausea severity score ≥ 4/10

Exclusion Criteria:

  • 1. Require IV access
  • Inability to breathe in/out through the nose
  • Anosmia (self- or parental report)
  • Allergy to isopropyl alcohol or ondansetron
  • Current or history of alcohol abuse
  • Inability to communicate feeling nauseous
  • Inability to follow directions regarding taking deep breaths through the nose
  • Known prolonged QT interval
  • Pregnancy
  • Received antiemetics within the last 8 hours
  • Currently taking apomorphine

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Inhaled Isopropyl Alcohol

If the subject is assigned to receive the isopropyl alcohol pad group, an isopropyl alcohol pad (Covidien Webcol 2 ply prep pad, saturated with 70% isopropyl alcohol) will be given to the subject, or the legal guardian. The alcohol pad will be held 1-2 cm under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed during the Emergency Department (ED) stay.

Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares

Autres noms:
  • WebCol
Comparateur actif: Oral Ondansetron

If the subject is assigned to receive ondansetron treatment, subject will be provided with 4 mg ondansetron oral disintegrating tablet (ODT) for treatment.

4 mg oral disintegrating ondansetron tablet once

Autres noms:
  • Zofran
Comparateur placebo: Inhaled Placebo

If the subject is assigned to receive the inhaled placebo, a normal saline pad (Hygea sterile saline wipe) will be given to the subject or the legal guardian. The saline wipe will be held under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed.

Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares

Autres noms:
  • Solution saline normale inhalée'

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Nausea Score at 30 Minutes
Délai: 30 minutes post-intervention as compared to baseline

Baxter Animated Retching Faces nausea score, 0-10 with higher score meaning worse nausea

30 minutes post-intervention as compared to baseline
Change in Nausea Score at 10 Minutes
Délai: 10 minutes post-interventnon as compared to baseline

Baxter Animated Retching Faces nausea score, 0-10 with higher score meaning worse nausea

10 minutes post-interventnon as compared to baseline
Change in Nausea Score at Discharge
Délai: At ED discharge (assessed up to 10 hours) as compared to baseline

Baxter Animated Retching Faces nausea score, 0-10 with higher score meaning worse nausea

At ED discharge (assessed up to 10 hours) as compared to baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Vomiting
Délai: From intervention to time of ED discharge (assessed up to 10 hours)

Number of episodes of vomiting post-intervention

From intervention to time of ED discharge (assessed up to 10 hours)
Parent/Caregiver Satisfaction
Délai: At time of ED discharge (assessed up to 10 hours)

Patient's parent/caregiver satisfaction score (very dissatisfied, dissatisfied, neutral, satisfied, very satisfied)

At time of ED discharge (assessed up to 10 hours)
Nurse Satisfaction in Ease of Administering the Treatment
Délai: At time of ED discharge (assessed up to 10 hours)

Patient's bedside nurse satisfaction score (very difficult, somewhat difficult, neutral, somewhat easy, very easy)

At time of ED discharge (assessed up to 10 hours)
Length of Stay
Délai: From arrival to time of ED discharge (assessed up to 10 hours)

Length of patient's stay in the emergency department

From arrival to time of ED discharge (assessed up to 10 hours)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Alana Koehler, MD, SUNY Buffalo
  • Directeur d'études: Heather Territo, MD, SUNY Buffalo

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 avril 2022

Achèvement primaire (Estimé)

30 juin 2027

Achèvement de l'étude (Estimé)

30 juin 2027

Dates d'inscription aux études

Première soumission

1 juin 2022

Première soumission répondant aux critères de contrôle qualité

12 juin 2022

Première publication (Réel)

14 juin 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

21 septembre 2026

Dernière vérification

1 octobre 2025

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner